- May 25, 2021Source: YaleNews
Researchers Create Cellular Blueprint of Healthy Lungs
- August 16, 2020Source: Youtu
Demystifying pulmonary fibrosis with single cell RNA sequencing
- July 08, 2020Source: YaleNews
Yale, Baylor Create Detailed Atlas of Cellular Change in Lungs with Fibrosis
- April 03, 2020
Have a Condition That Can Affect Breathing? What You Need to Know About COVID-19.
- February 18, 2020Source: TuftsNow
Terriers Test a Therapy for Lung Disease
Welcome to The Kaminski Lab!
Dr Kaminski’s research is currently focused on improving our understanding and treatment of chronic lung diseases such as Idiopathic Pulmonary Fibrosis (IPF), a chronic lung disease characterized by progressive scarring of the lungs, as well as COPD, Sarcoidosis and Asthma. His group applies cutting edge high throughput technologies that measure changes in the sequence, expression or regulation of all the genes in the human genome to identify the mechanisms, improve the diagnosis and develop new therapeutic targets.
While lung diseases have traditionally been defined by objective clinical characteristics, these characteristics usually do not predict outcome, response to therapy and morbidity and mortality. To realize the promise of personalized medicine, the current diagnostic approaches to chronic lung diseases should be modified to include both information on the genetics, epigenetics and microbiome of the individual and the diseased organ as well dynamic molecular information that can more precisely define the etiology, stage, and the biological activity of the disease process.
Principal Investigator
Naftali Kaminski, MD
Boehringer Ingelheim Pharmaceuticals, Inc. Professor of Medicine (Pulmonary)